An Open-label Study Evaluating MM402 (R-MDMA) in Adults With Autism Spectrum Disorder

This is a single-center, open-label study to evaluate the effects after a single administration of MM402 (R-MDMA) to adults with Autism Spectrum Disorder (ASD). This study will enroll approximately twenty adults with ASD aged 18 to 65 years of age. MM402, a form of MDMA, may change social and emotional thinking or feelings in adults with ASD. This type of drug generally makes people feel more connected, social, and emotionally open with others. This single-dose study investigates whether MM402 may support social communication in adults with ASD.

You may me eligible to participate if you are:
– 18 to 65 years old
– Experiencing challenges with socialization or communication
– Diagnosed with Autism Spectrum Disorder (ASD)

This study can last up to nine weeks and will include 5 in-person visits and 1 phone call. On dosing day you will:
– Take one dose of the study drug
– Remain onsite for a minimum of 8 hours
– Be monitored for safety by trained medical staff throughout the day
– Answer questionnaires and complete tests on the way you socialize and communicate
No overnight stays needed.

Your participation will help advance research in Autism Spectrum Disorder (ASD), including helping researchers discover new treatments. If you take part, we may learn new ways to support those with ASD.